Vertex Pharmaceuticals Incorporated (VRTX) Fundamentals — Income, Balance Sheet & Cash Flow | MarketCI

Vertex Pharmaceuticals Incorporated (VRTX) Fundamentals — Income, Balance Sheet & Cash Flow | MarketCI | MarketCI

VRTX

Market Closed

Vertex Pharmaceuticals Incorporated

NASDAQHealthcare Biotechnology

6.10K employees

CEO: Reshma Kewalramani

Founded: 1991

$451.63

+$0.00(+NaN%)

Market Cap

114.63B

Beta

0.31

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

Financial Statements

Comprehensive breakdown of financial statements and performance metrics

Gross Margin

85.0%

8.2%

CAGR: 11.4%

Profit after direct costs

Operating Margin

39.4%

-2144.1%

CAGR: 14.4%

Core business profitability

Net Margin

32.7%

-838.1%

CAGR: 14.0%

Bottom line profitability

Revenue Growth

9.6%

YoY

CAGR: 12.4%

Top line growth rate

Revenue Flow Analysis

Visual flow showing how VRTX allocates revenue across expenses and profit

Fiscal Year 2025

Revenue Distribution

Flow of revenue through cost categories to net income

Gross Margin

85.0%

$10.27B

Operating Margin

39.4%

$4.76B

Net Margin

32.7%

$3.95B

Detailed Income Statement

Complete profit and loss breakdown with margin analysis and historical comparison

Item	2021	2022	2023	2024	2025	YoY Change
Total Revenue	7.57B	8.93B	9.87B	11.02B	12.07B	9.6%
Cost of Revenue	(904.20M)	(1.08B)	(1.26B)	(1.53B)	(1.81B)	18.1%
Gross Profit	6.67B	7.85B	8.61B	9.49B	10.27B	8.2%
Operating Expenses
Research & Development	(3.05B)	(2.66B)	(3.16B)	(3.63B)	(3.75B)	3.4%
Selling, General & Administrative	(840.10M)	(944.70M)	(1.14B)	(1.46B)	(1.75B)	19.7%
Depreciation & Amortization	(125.60M)	(148.30M)	(181.30M)	(205.80M)	(207.20M)	0.7%
Operating Income (EBIT)	2.78B	4.31B	3.83B	-232.90M	4.76B	-2144.1%
Non-Operating Items
Interest Income	4.90M	144.60M	614.70M	598.10M	490.90M	-17.9%
Interest Expense	(61.50M)	(54.80M)	(44.10M)	(30.60M)	(13.30M)	-56.5%
Other Income/Expenses (Net)	-51.70M	-75.00M	547.80M	481.40M	-117.50M	-124.4%
Income Before Tax	2.73B	4.23B	4.38B	248.50M	4.64B	1768.5%
Income Tax Expense	(388.30M)	(910.40M)	(760.20M)	(784.10M)	(690.00M)	-12.0%
Net Income	2.34B	3.32B	3.62B	-535.60M	3.95B	-838.1%
Per Share Metrics
Earnings Per Share (Basic)	$9	$13	$14	$-2	$15	-843.3%
Weighted Avg Shares Outstanding	257.70M	256.10M	257.70M	257.50M	255.70M	-0.7%
Weighted Avg Shares Outstanding (Diluted)	259.90M	259.10M	260.50M	257.90M	258.00M	0.0%
EBITDA	2.92B	4.44B	4.61B	486.30M	4.86B	900.1%

Explore VRTX

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

VRTX in the Healthcare

Large Cap

Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →